Hyperoxaluria clinical trials
The registry lists 51 studies for Hyperoxaluria across more than 10 countries. 11 are recruiting or about to start. 14 of them are mainly about Hyperoxaluria (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-13. Counting its 2 narrower conditions too, such as Hyperoxaluria, Primary: 81 studies, 19 open.
Get an email when these change. Save the Hyperoxaluria studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Mayo Clinic (13) · Allena Pharmaceuticals (6) · OxThera (4) · Alnylam Pharmaceuticals (4) · YolTech Therapeutics Co., Ltd (2) · University of Alabama at Birmingham (2) · London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's (2) · Aga Khan University (2)
What is being tested here
Drugs under test in Hyperoxaluria studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Dec 2026Validation Testing for Plasma Oxalate Levels in the Biochemical Laboratory at the Galilee Medical Center, in Collaboration With the Biochemistry Laboratory at CHARITE Hospital in Berlin, and Testing the Relationship Between Oxalate Levels and Vitamin C Levels in Plasma · Western Galilee Hospital-Nahariya
- Aug 2027Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1) · YolTech Therapeutics Co., Ltd
- Oct 2027Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1) · YolTech Therapeutics Co., Ltd
Who these studies take
Of the 9 Hyperoxaluria studies recruiting now, 5 (56%) set no upper age limit and 0 (0%) stop at 75 or younger. 6 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (22%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 6 (67%) | 6 (67%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 9 (100%) | 9 (100%) |
| 50 | 9 (100%) | 9 (100%) |
| 65 | 9 (100%) | 9 (100%) |
| 75 | 9 (100%) | 9 (100%) |
| 85 | 6 (67%) | 6 (67%) |
Across all 51 studies, recruiting or not: 25% stop at 75 or younger and 16% at 65; 51% take children; 2% are for women only and 0% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 → or search them.
- O. Formigenes Colonization in Calcium Oxalate Kidney Stone DiseaseRecruitingNCT06330246Not applicable1 country
- Gut Oxalate Absorption in Calcium Oxalate Stone DiseaseRecruitingNCT06331546Not applicable1 country
- Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)RecruitingNCT07587021Phase 21 country
- Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)RecruitingNCT07776626Phase 11 country
- Prospective Research Rare Kidney Stones (ProRKS)RecruitingNCT027802974 countries
- Rare Kidney Stone Consortium BiobankRecruitingNCT020263881 country
- Rare Kidney Stone Consortium Patient RegistryRecruitingNCT005885622 countries
- Validation Testing for Plasma Oxalate Levels in the Biochemical Laboratory at the Galilee Medical Center, in Collaboration With the Biochemistry Laboratory at CHARITE Hospital in Berlin, and Testing the Relationship Between Oxalate Levels and Vitamin C Levels in PlasmaNot yet recruitingNCT06578754
- Gut Kidney Axis in Enteric HyperoxaluriaRecruitingNCT05124886Not applicable1 country
- Monogenic Kidney Stone - Genetic TestingRecruitingNCT033058351 country
- Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone PatientsNot yet recruitingNCT05443932Phase 41 country
- A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.CompletedNCT06481150Phase 41 country
- Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and NephrolithiasisCompletedNCT03346369Phase 31 country
- Oxalate Excretion Profile in Patients With a Heterozygous Mutation of the AGXT (Alanine-glyoxylate Aminotransferase) GeneCompletedNCT06283082Not applicable1 country
- A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1CompletedNCT04152200Phase 311 countries
- A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1CompletedNCT03905694Phase 35 countries
- A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)TerminatedNCT02795325Phase 12 countries
- A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And HyperoxaluriaWithdrawnNCT06138327Phase 11 country
- An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1CompletedNCT03350451Phase 25 countries
- Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric HyperoxaluriaCompletedNCT04629170Phase 11 country
- Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1Approved for marketingNCT04125472
- Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult SubjectsTerminatedNCT04909723Phase 1/22 countries
- Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel SyndromeCompletedNCT05377112Early Phase 11 country
- Plasma Oxalate in Patient With Short BowelCompletedNCT041197651 country
- Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric HyperoxaluriaTerminatedNCT03847090Phase 316 countries
- Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on DialysisCompletedNCT02000219Phase 21 country
- A Pilot Study of Oxalate Absorption in Secondary HyperoxaluriaCompletedNCT03095885Not applicable1 country
- Reference Interval of Spot Urinary Oxalate to Creatinine Ratio in ChildrenCompletedNCT047560241 country
- Spot Urine Oxalate to Creatinine Ratio and 24 Hours Urinary OxalateCompletedNCT045713591 country
- Effect of Oxalate and Urate Metabolism on CKD EvolutionStatus unknownNCT043999151 country
- Enteric Oxalate Absorption Study in Unclassified HyperoxaluriaCompletedNCT00588120Phase 11 country
- Evaluate ALLN-177 in Patients With Enteric HyperoxaluriaCompletedNCT03456830Phase 37 countries
- Primary Hyperoxaluria Mutation Genotyping/PhenotypingCompletedNCT023406891 country
- Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With HyperoxaluriaCompletedNCT02289755Phase 21 country
- Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney StonesCompletedNCT02503345Phase 21 country
- Hydroxyproline Influence on Oxalate MetabolismCompletedNCT02038543Phase 1/21 country
- Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 DaysCompletedNCT02547805Phase 21 country
- Effect of Over-the-counter Dietary Supplements on Kidney Stone RiskCompletedNCT02404701Not applicable1 country
- Primary Hyperoxaluria Mutation GenotypingCompletedNCT005892251 country
- Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary HyperoxaluriaCompletedNCT02012985Phase 1/23 countries
- Renal Protective Effect of ACEI and ARB in Primary HyperoxaluriaWithdrawnNCT00280215Phase 3
- International Registry for Primary HyperoxaluriaWithdrawnNCT008758231 country
- Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary HyperoxaluriaCompletedNCT00283387Phase 21 country
- Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria PatientsCompletedNCT00638703Phase 2/31 country
- Phase 2/3 Oxabact StudyCompletedNCT01037231Phase 2/33 countries
- Oxazyme in Patients With HyperoxaluriaCompletedNCT01127087Phase 1/21 country
- Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphateCompletedNCT01281878Phase 21 country
- Use of Oral Probiotics to Reduce Urinary Oxalate ExcretionCompletedNCT00587041Phase 1/21 country
- Oral Antibiotic Treatment of Helicobacter Pylori Reduces Intestinal Colonization Rates With Oxalobacter FormigenesCompletedNCT01300039
- Proteomic Study of Urinary Stone DiseaseCompletedNCT001994591 country